1. |
Ferlay J, Shin HR, Bray F,et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN2008. Int J Cancer, 2010, 127(12): 2893-2917.
|
2. |
Miller KD, Siegel RL, Lin CC,et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin, 2016, 66(4): 271-289.
|
3. |
Parums DV. Current status of targeted therapy in non-small cell lung cancer. Drugs Today (Barc), 2014, 50(7): 503-525.
|
4. |
Jackman DM, Miller VA, Cioffredi LA,et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res, 2009, 15(16): 5267-5273.
|
5. |
Cufer T, Ovcaricek T, O'Brien ME. Systemic therapy of advanced non-small cell lung cancer: major-developments of the last 5-years. Eur J Cancer, 2013, 49(6): 1216-1225.
|
6. |
秦虹, 曾川, 范卫东, 等. 2016 年 ASCO 会议非小细胞肺癌免疫治疗的相关进展. 中华肺部疾病杂志(电子版), 2016, 9(4): 464-466.
|
7. |
Hamanishi J, Mandai M, Konishi I. Immune checkpoint inhibition in ovarian cancer. Int Immunol, 2016, 28(7): 339-348.
|
8. |
Gettinger SN, Horn L, Gandhi L,et al. Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. J of Clin Oncol, 2015, 33(18): 2004-2012.
|
9. |
Zhu L, Jing S, Bing W,et al. Anti-PD-1/PD-L1 Therapy as a Promising Option for Non-Small Cell Lung Cancer: a Single arm Meta-Analysis. POR, 2016, 22(2): 1-9.
|
10. |
Hodi FS, O'Day SJ, McDermott DF,et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med, 2010, 363(8): 711-723.
|
11. |
Topalian SL, Hodi FS, Brahmer JR,et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med, 2012, 366(26): 2443-2454.
|
12. |
Ribas A, Kefford R, Marshall MA,et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. In J Clin Oncol, 2013, 31(5): 616-622.
|
13. |
Zatloukal P, Heo DS, Park K,et al. Randomized phase II clinical trial comparing tremelimumab with best supportive care following first-line platinum-based therapy in patients with advanced non-small cell lung cancer. Asco Meeting Abstracts, 2009, 27: 15S.
|
14. |
Dizon DS, Krilov L, Cohen E,et al. Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol, 2016, 34(9): 987-1011.
|
15. |
李然, 王睿, 汤建华, 等. 紫杉醇治疗小细胞肺癌的系统评价. 中国循证医学杂志, 2008, 8(10): 851-860.
|
16. |
Ishida Y, Agata Y, Shibahara K,et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. Embo J, 1992, 11(11): 3887-3895.
|
17. |
Okazaki T, Maeda A, Nishimura H,et al. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci USA, 2001, 98(24): 13866-13871.
|
18. |
Moreno BH, Parisi G, Robert L,et al. Anti-PD-1 Therapy in Melanoma. Semin Oncol, 2015, 42(3): 466-473.
|
19. |
Zimmerman MP, Mehr SR. Targeted programmed cell death in lung cancer treatment. Am J Manag Care, 2014, 20(5): 3.
|
20. |
Wolchok JD. PD-1 Blockers. Cell, 2015, 162(5): 937.
|
21. |
Calles A, Liao X, Sholl LM,et al. Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer. J Thorac Oncol, 2015, 10(12): 1726-1735.
|
22. |
Zhu L, Jing S, Wang B,et al. Anti-PD-1/PD-L1 Therapy as a Promising Option for Non-Small Cell Lung Cancer: a Single arm Meta-Analysis. POR, 2016, 22(2): 331-339.
|
23. |
Carbognin L, Pilotto S, Milella M,et al. Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. PLoS One, 2015, 10(6): e0130142.
|
24. |
Zhang T, Xie J, Arai S,et al. The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis. Oncotarget, 2016, 7(45): 73068-73079.
|
25. |
Rossi A, Pasquale R, Esposito C,et al. Should epidermal growth factor receptor tyrosine kinase inhibitors be considered ideal drugs for the treatment of selected advanced non-small cell lung cancer patients? Cancer Treat Rev, 2013, 39(5): 489-497.
|
26. |
Zhou C, Wu YL, Chen G,et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol, 2011, 12(8): 735-742.
|
27. |
Lynch TJ, Bell DW, Sordella R,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med, 2004, 350(350): 2129-2139.
|
28. |
Borghaei H, Paz-Ares L, Horn L,et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med, 2015, 373(17): 1627-1639.
|
29. |
Brahmer J, Reckamp KL, Baas P,et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med, 2015, 373(2): 123-135.
|
30. |
Weber JS, Minor DR, D'Angelo SP,et al. A phase 3 randomized, open-label study of nivolumab (anti-pd-1; bms-936558; ono-4538) versus investigator's choice chemotherapy (icc) in patients with advanced melanoma after prior anti-ctla-4 therapy. Ann Oncol, 2014, 25(suppl 4): 1210.
|
31. |
Fehrenbacher L, Spira A, Ballinger M,et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet, 2016, 387(10030): 1837-1846.
|
32. |
Herbst RS, Baas P, Kim DW,et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet, 2015, 387(10027): 1540-1550.
|